My name is Teruki Isobe, urologist of Nagoya CIty University hospital in Japan. This is my third year to study urology and first time to enjoy AUA anual meeting. This time I'll present about "Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: A multicenter retrospective analysis."
Disclosure information not submitted.